Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States

Javier Valero-Elizondo, MD, MPH,a,b,* Fouad Chouairi, BS,c,* Rohan Khera, MD, MS,c,d Gowtham R. Grandhi, MD, MPH,a Anshul Saxena, PhD,1 Haider J. Warraich, MD,e Salim S. Virani, MD, PhD,f Haidar J. Warraich, MD, g,h Harlan M. Krumholz, MD, SM,c,d,l Nestor F. Esnaola, MD, MPH, MBA,m,n Khurram Nasir, MD, MPH, MSCa,b

ABSTRACT

BACKGROUND Financial toxicity (FT) is a well-established side-effect of the high costs associated with cancer care. In recent years, studies have suggested that a significant proportion of those with atherosclerotic cardiovascular disease (ASCVD) experience FT and its consequences.

OBJECTIVES This study aimed to compare FT for individuals with neither ASCVD nor cancer, ASCVD only, cancer only, and both ASCVD and cancer.

METHODS From the National Health Interview Survey, we identified adults with self-reported ASCVD and/or cancer between 2013 and 2018, stratifying results by nonelderly (age <65 years) and elderly (age ≥65 years). We defined FT if any of the following were present: any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost.

RESULTS The prevalence of FT was higher among those with ASCVD when compared with cancer (54% vs. 41%; p < 0.001). When studying the individual components of FT, in adjusted analyses, those with ASCVD had higher odds of any difficulty paying medical bills (odds ratio [OR]: 1.22; 95% confidence interval [CI]: 1.09 to 1.36), inability to pay bills (OR: 1.25; 95% CI: 1.04 to 1.50), cost-related medication nonadherence (OR: 1.28; 95% CI: 1.08 to 1.51), food insecurity (OR: 1.39; 95% CI: 1.17 to 1.64), and foregone/delayed care due to cost (OR: 1.17; 95% CI: 1.01 to 1.36). The presence of ≥3 of these factors was significantly higher among those with ASCVD and those with both ASCVD and cancer when compared with those with cancer (23% vs. 30% vs. 13%, respectively; p < 0.001). These results remained similar in the elderly population.

CONCLUSIONS Our study highlights that FT is greater among patients with ASCVD compared with those with cancer, with the highest burden among those with both conditions. (J Am Coll Cardiol CardioOnc 2021;3:236–46) © 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Financial toxicity (FT) refers to the financial strain that patients experience while accessing health care, and has been widely researched in cancer patients (1). Used interchangeably with “financial hardship,” “financial (di)stress,” “(high) financial burden,” “economic burden,” and “economic hardship” (2), it has been reported that a large proportion of patients with cancer experience FT (3–5). This affliction is not limited to cancer diagnosis, but also manifests as the impaired health of patients following treatment and survivorship (6). These insights have also been directed toward implementation of FT-specific interventions for better screening, social support, and care for patients with cancer (7–10).

Although there has been an emphasis on understanding and remediating FT in patients with cancer (3), this phenomenon has been studied less frequently among patients with atherosclerotic cardiovascular disease (ASCVD). The extent of FT and how it manifests might differ between patients with ASCVD and cancer. For example, patients with cancer may have short bursts of high expenditures with chemotherapy, whereas ASCVD incurs a more chronic economic burden related to the costs of drugs, procedures, clinician visits, and hospital stays (11). The economic burden that ASCVD confers to patients and families who experience it has been described in the last few years (12–15). Additionally, with prolonged survival following the diagnosis of cancer, the cardiac toxicity of some treatments, and better treatment options for ASCVD, the population of patients with simultaneous ASCVD and cancer is growing. Without the ability to pay, patients can experience financial health and non-health-related difficulties, such as difficulty paying medical bills, financial distress, cost-related medication nonadherence, and food insecurity, and may forego or delay care due to cost (16–19).

However, no studies to date have contrasted the FT incurred in patients with ASCVD and/or cancer, which are currently the 2 leading causes of death in the United States (20). The current study, using a nationally representative sample of the United States, compared the financial burden of health care on adult patients with neither ASCVD nor cancer, ASCVD only, cancer only, and both ASCVD and cancer.

**METHODS**

**STUDY DESIGN.** We utilized 6 years of data (2013 to 2018) from the NHIS (National Health Interview Survey). The NHIS, a database compiled by the National Center for Health Statistics/Center for Disease Control and Prevention, is constructed from annual, cross-sectional national surveys that incorporate complex, multistage sampling to provide estimates on the noninstitutionalized U.S. population (21). The NHIS questionnaire is divided into 4 core components: Household Composition, Family Core, Sample Child Core, and Sample Adult Core (21). The Household Composition file collects basic information and relationship information about all persons in a household. The Family Core file collects sociodemographic characteristics, basic indicators of health status, activity limitations, injuries, health insurance coverage, and access to, and utilization of, health care services. From each family, 1 sample child and 1 sample adult are randomly selected to gather more detailed information. This study utilized the Sample Adult Core files (with relevant variables added from the Family Core files), which are supplemented with demographic and socioeconomic characteristics, health status, health care services, and health-related behaviors on the U.S. adult population (21). Because NHIS data are publicly available and deidentified, this study was exempt from institutional review board approval (22).

**STUDY POPULATION.** We used a self-reported diagnosis of coronary or cerebrovascular disease to identify patients with ASCVD. Specifically, individuals were included if they reported having coronary artery disease (“yes” to any of the following 3 questions: “Have you ever been told by a doctor or other health professional that you had...coronary heart disease,” “…angina, also called angina pectoris,” or “…a heart attack [also called myocardial infarction?]”) and/or stroke (“yes” to the following question: “Have you ever been told by a doctor or other health professional that you had a stroke?”) were classified as having...
ASCVD. Similarly, individuals that answered “yes” to the question, “Have you ever been told by a doctor or other health professional that you had cancer or a malignancy of any kind?” were classified as having cancer. These methods of diagnosis ascertainment have been used in previous literature (12,23). For our main analyses, we included only non-elderly (≥18 to <65 years of age) adults to capture the population without universal financial protections from public insurance. As a subanalysis, we further extended our study population to elderly (≥65 years of age) adults.

**STUDY OUTCOMES. Financial toxicity.** For the purposes of this paper, we defined FT as having any of the following: difficulty paying medical bills, inability to pay them at all, high financial distress, cost-related medication nonadherence, food insecurity, and/or delayed/foregone care due to cost. The specific questions and definitions for each FT component are presented in Supplemental Table 1.

**Difficulty paying medical bills.** The following questions were used to assess the study population having “any difficulty paying medical bills”:

- “In the past 12 months, did you/anyone in your family have problems paying or were unable to pay any medical bills? Include bills for doctors, dentists, hospitals, therapists, medication, equipment, nursing home or home care,” or
- “Do you/anyone in your family currently have any medical bills that are being paid off over time? This could include medical bills being paid off with a credit card, through personal loans, or bill paying arrangements with hospitals or other providers. The bills can be from earlier years as well as this year.”

This approach has been previously employed in other studies and surveys (24,25). Additionally, for individuals who answered “yes” to having difficulty paying bills, a follow-up question was asked: “Do you/does anyone in your family currently have any medical bills that you are unable to pay at all?” Individuals who answered “yes” to this question were studied as a separate group—those who were “unable to pay bills at all.”

**High financial distress.** Financial distress was derived from 6 questions regarding the level of concern with several financial matters, including: lack of retirement funds, ability to pay medical costs of serious illness, maintaining an acceptable quality of living, ability to pay day-to-day health care costs, inability to pay monthly bills, and inability to pay rent/mortgage/housing costs (Supplemental Table 1).

The questions were responded to on a 4-point scale, ranging from “not worried at all” to “very worried.” An aggregate score was created, ranging from 6 to 24, a higher score indicating increased levels of financial distress (26). Participants within the highest quartile were designated as experiencing high levels of financial distress.

**Cost-related medication nonadherence.** Cost-related medication nonadherence was defined as a survey responder reporting any of the following behaviors to save money in the last 12 months: skipping medication doses, taking less medicine, or delaying filling a prescription (Supplemental Table 1).

**Food insecurity.** Food security in the last 30 days was created based on the 10-item questionnaire as recommended by the U.S. Department of Agriculture Economic Research Service (Supplemental Table 1) (27,28), and constructed per the NHIS instructions (28). In questions about frequency of occurrence in the past 30 days, answers of ≥ 3 days were considered affirmative. A raw score ranging from 0 to 10 was calculated, with the following categories: food secure (score 0 to 2), low food security (score 3 to 5), and very low food security (score 6 to 10). For this study’s purposes, food insecurity included those who had either low or very low food security, as is common in practice (29).

**Delayed/foregone care due to cost.** Delayed and/or foregone care due to cost was assessed by asking individuals whether, within the past year, medical care had been delayed due to cost, or if they needed but did not receive medical care due to cost (30).

**COVARIATES.** Other covariates included in this study were age, sex, race/ethnicity, family income, education, insurance status, region, cardiovascular risk factor (CRF) profile, number of chronic comorbidities, and for individuals with cancer, years since diagnosis. Categorical variables were classified as follows: 2 categories for sex; 3 categories for race/ethnicity (non-Hispanic White, non-Hispanic Black, and Hispanic); 2 categories for family income (based on percent of family income to the federal poverty limit from the Census Bureau: high/middle-income [≥200%], low-income [<200%]); 2 categories for education (some college or higher, high school/GED or less than high school); 2 categories for insurance status (insured, uninsured), and 4 categories for geographic region (Northeast, Midwest, South, and West). CRF profile was calculated by determining, via self-report, whether individuals had 1 or more of the following: diagnosis of hypertension, diabetes mellitus or high cholesterol, obesity (calculated body mass index ≥30 kg/m²), current smoker, or insufficient physical activity (based on not participating in >150
min/week of moderate-intensity aerobic physical activity, >75 min/week of vigorous-intensity aerobic physical activity, or a total combination of ≥150 min/week of moderate/vigorous-intensity aerobic physical activity). Based on the presence of these individual risk factors, individuals were categorized as “poor” (≥4 CRFs), “average” (2 to 3 CRFs), and “optimal” (0 to 1 CRF) (31,32). Self-reported chronic comorbidities, including emphysema, chronic obstructive pulmonary disease, asthma, gastrointestinal ulcer, arthritis (including arthritis, gout, fibromyalgia, rheumatoid arthritis, and systemic lupus erythematosus), any kind of liver condition, or “weak/failing” kidneys, were aggregated, and categorized as having 0, 1, or ≥2. For individuals with cancer, time since diagnosis was measured in years, and presented as both continuous, and categorized as ≥0 to <5, ≥5 to <15, and ≥15 years.

**STATISTICAL ANALYSIS.** Chi-square tests were used to compare categorical variables, and weighted proportions were used to study prevalence. Continuous variables were reported as medians with interquartile range. Categorical variables were reported as unweighted counts with their accompanying weighted proportions (in tables), and as weighted proportions with 95% confidence interval (CI) (in figures). Further, we used linear regression to test for linear trends of the prevalence of FT measures between disease groups. Unadjusted and adjusted logistic regression models were used to measure the association between FT prevalence and disease group (neither ASCVD nor cancer, ASCVD, cancer, or both ASCVD and cancer), and were reported as odds ratios (ORs) with 95% CIs. Adjusted models included variables that have been correlated with presence and/or risk for FT (e.g., income and insurance status), or that are clinically significant (e.g., age, cardiovascular risk factors, and comorbidities). We used the Akaike Information Criterion to determine the optimal variables to include in our adjusted model. The full list of explanatory variables included age, sex, race/ethnicity, family income, education, insurance status, geographic region, cardiovascular risk factor profile, and comorbidities for all outcome measures; in the case of high financial distress, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost, burden from medical bills was also included due to the risk of confounding. Similar models were constructed for the individual components of FT. Variance estimation for the entire pooled cohort was obtained from the Integrated Public Use Microdata Series (33). For all statistical analyses, p < 0.05 was considered statistically significant. All analyses were carried out using Stata version 16 (StataCorp, LP, College Station, Texas). All analyses were survey-specific considering the complex design of the NHIS survey.

**RESULTS**

**NON-ELDERLY POPULATION.** From 2013 to 2018, the NHIS total sample of non-elderly (≥18 to <65 years of age) adults was 141,826, of which 6,887 (weighted prevalence: 4.5% [95% CI: 4.4% to 4.7%]), 6,093 (weighted prevalence: 3.8% [95% CI: 3.7% to 4.0%]), and 971 (weighted prevalence: 0.6% [95% CI: 0.56% to 0.65%]) had cancer, ASCVD, and both ASCVD and cancer, respectively. This translates to 8.9, 7.5, and 1.2 million non-elderly U.S. adults yearly, respectively (Table 1).

Most individuals in the non-elderly population were 40 to 64 years of age, insured, and White. Women were more likely to report having cancer, with a majority coming from middle-/high-income households and with a higher education level. In contrast, those reporting ASCVD (with or without cancer) were evenly distributed by sex, education, and income levels, although with a shift toward a more unfavorable CRF profile (Table 1). Among the non-elderly adults with cancer, the most frequently reported cancers included skin (nonmelanoma), breast, cervix, prostate, and “other” (Supplemental Table 2). Similar patterns were observed in the population that reported both ASCVD and cancer.

Prevalence of FT measures by underlying condition are comprehensively depicted in our Central Illustration. Any FT was present to a higher extent across disease categories from neither ASCVD nor cancer (38.3% [95% CI: 37.8% to 38.9%]), to cancer (41.0% [95% CI: 39.5% to 42.6%]), to ASCVD (54.1% [95% CI: 52.4% to 55.8%]), and both ASCVD and cancer; 54.5% [95% CI: 50.3% to 58.7%]) (p trend <0.001) (Central Illustration). Difficulty paying medical bills was significantly higher for individuals with ASCVD (with or without cancer; 44.8% [95% CI: 43.1% to 46.5%] and 47.4% [95% CI: 43.1% to 51.7%], respectively) when compared with those with cancer (35.0% [95% CI: 33.5% to 36.6%]). When analyzing those with the highest burden from medical bills—those with an inability to pay bills at all—a statistically significant trend was also seen when comparing cancer (10.1% [95% CI: 9.0% to 11.3%]) versus ASCVD (18.2% [95% CI: 16.9% to 19.5%]) versus both (23.2% [95% CI: 19.8% to 26.8%]) (p trend <0.001). Overall, the same pattern (i.e., ASCVD and cancer > ASCVD >
From the National Health Interview Survey, 2013 to 2018

General Characteristics Among Non-Elderly Adults With Cancer and/or ASCVD,

### TABLE 1

| Years since cancer diagnosis | Values are n, n (%), or median (interquartile range). All p values for comparison between groups were <0.001. ASCVD = atherosclerotic cardiovascular disease; CRF = cardiovascular risk factor; GED = general equivalency diploma; HS = high school. |
|---|---|
| **Sample** | | |
| Neither ASCVD Nor Cancer | Cancer Only | ASCVD Only | Both ASCVD and Cancer |
| | 127,875 | 6,887 | 6,093 | 971 |
| Weighted sample | 178,640,421 | 8,865,357 | 7,493,768 | 1,173,167 |
| Age category, yrs | | | | |
| 18-39 | 61,680 (50.7) | 979 (14.3) | 717 (13.3) | 66 (7.8) |
| 40-64 | 66,195 (49.3) | 5,908 (85.7) | 5,376 (86.7) | 905 (92.2) |
| Sex | | | | |
| Male | 59,431 (49.3) | 2,350 (36.2) | 3,390 (59.1) | 441 (48.7) |
| Female | 68,444 (50.7) | 4,537 (73.8) | 2,703 (40.9) | 530 (51.3) |
| Race/ethnicity | | | | |
| Non-Hispanic White | 78,011 (61.7) | 5,626 (83.6) | 3,801 (64.9) | 762 (82.1) |
| Hispanic | 22,416 (18.4) | 526 (7.5) | 838 (14.8) | 72 (8.1) |
| Female | 68,444 (50.7) | 4,537 (73.8) | 2,703 (40.9) | 530 (51.3) |
| Race/ethnicity | | | | |
| Non-Hispanic White | 78,011 (61.7) | 5,626 (83.6) | 3,801 (64.9) | 762 (82.1) |
| Hispanic | 22,416 (18.4) | 526 (7.5) | 838 (14.8) | 72 (8.1) |
| Family income | | | | |
| Low income | 42,332 (30.5) | 1,826 (22.1) | 3,059 (49.3) | 497 (54.7) |
| Region | | | | |
| Northeast | 20,323 (17.4) | 1,120 (17.3) | 894 (15.1) | 141 (15.8) |
| Midwest | 27,750 (22.2) | 1,602 (23.6) | 1,344 (23.6) | 213 (24.1) |
| South | 45,443 (36.3) | 2,379 (37.2) | 2,566 (42.7) | 415 (43.0) |
| West | 34,359 (26.0) | 1,786 (24.0) | 1,289 (18.6) | 202 (22.0) |
| Education | | | | |
| College or higher | 82,769 (64.6) | 4,777 (70.4) | 2,993 (49.8) | 425 (43.2) |
| HS/GED or less than HS | 44,652 (35.4) | 2,094 (29.6) | 3,076 (49.8) | 425 (43.2) |
| Insurance status | | | | |
| Insured | 107,418 (85.3) | 6,327 (92.9) | 5,335 (87.9) | 887 (82.1) |
| Uninsured | 19,816 (14.7) | 544 (7.1) | 740 (12.1) | 179 (17.9) |
| CRF profile | | | | |
| Optimal | 73,456 (61.2) | 2,952 (47.4) | 940 (17.9) | 142 (16.5) |
| Average | 41,420 (32.8) | 2,789 (41.2) | 2,637 (45.6) | 390 (45.2) |
| Poor | 8,187 (6.0) | 819 (11.3) | 2,131 (36.4) | 360 (38.3) |
| Comorbidities | | | | |
| 0 | 88,643 (70.8) | 3,203 (48.3) | 2,149 (37.9) | 210 (25.0) |
| 1 | 29,926 (22.7) | 2,259 (32.8) | 1,950 (32.5) | 270 (25.8) |
| ≥2 | 8,865,357 | 3,203 (48.3) | 2,149 (37.9) | 210 (25.0) |
| Years since cancer diagnosis | | | | |
| 0 to ≤5 | 2,989 (44.7) | 2,336 (38.8) | 287 (31.6) | 284 (26.8) |
| >5 to ≤15 | 1,562 (26.8) | 287 (31.6) | 287 (31.6) | 284 (26.8) |
| >15 | 2,336 (38.8) | 287 (31.6) | 287 (31.6) | 284 (26.8) |

Values are n, n (%), or median (interquartile range). All p values for comparison between groups were <0.001. ASCVD = atherosclerotic cardiovascular disease; CRF = cardiovascular risk factor; GED = general equivalency diploma; HS = high school.

Cancer > neither) was observed for high financial distress, cost-related medication nonadherence, food insecurity, and delayed/foregone medical care due to cost when comparing those reporting ASCVD (with or without cancer) versus cancer (all p trend <0.001).

In univariable logistic regression analysis, patients with both cancer and ASCVD had increased odds of any FT (OR: 1.93; 95% CI: 1.63 to 2.28). This was further observed in all of FT measures: any difficulty paying medical bills (OR: 2.27; 95% CI: 1.91 to 2.70), inability to pay medical bills at all (OR: 3.43; 95% CI: 2.83 to 4.16), high financial distress (OR: 2.46; 95% CI: 2.08 to 2.92), cost-related medication nonadherence (OR: 4.72; 95% CI: 3.86 to 5.78), food insecurity (OR: 3.19; 95% CI: 2.65 to 3.83), and foregone/delayed care due to cost (OR: 2.51; 95% CI: 2.08 to 3.03) when compared with patients who reported neither disease (Table 2). The presence of ASCVD with or without cancer was associated with an increased odds for all FT measures when compared with individuals with cancer, as evidenced by nonoverlapping CIs. In multivariable analysis, after adjusting for confounders including variables such as family income and insurance status, the effect sizes were attenuated but associations remained consistent and statistically significant: those with ASCVD and cancer had increased odds of being unable to pay medical bills at all, high financial distress, cost-related medication nonadherence, and foregone/delayed medical care, when compared with those with cancer (Table 2). Of note, even though effect sizes were larger (i.e., higher ORs), there were no statistical differences between the groups with ASCVD only and both ASCVD and cancer in adjusted analyses (interaction p = 0.39). Our findings further reinforce the notion that presence of ASCVD was a key determinant of the presence and severity of FT.

Furthermore, in a composite score of number of FT measures each individual had, we found that the prevalence of having ≥3 was 9% (≈17.2 million) among those with neither disease, 13% (≈25.3 million) among those with cancer, 23% (≈44.5 million) among those with ASCVD, and 30% (≈57.9 million) among those with both (p trend <0.001) (Figure 1).

**ELDERLY POPULATION.** From 2013 to 2018, the NHIS total sample of elderly (>65 years of age) adults was 48,287, of which 8,457 (weighted prevalence: 18.1% [95% CI: 17.7% to 18.6%]), 8,167 (weighted prevalence: 16.9% [95% CI: 16.4% to 17.3%]), and 3,211 (weighted prevalence: 6.8% [95% CI: 6.5% to 7.1%]) had cancer, ASCVD, and both, respectively. This translates to 8.6, 8.0, and 3.2 million elderly U.S. adults yearly (Supplemental Table 3). Virtually all patients in this age category were White and insured, and the majority were from middle/high-income households. Individuals with ASCVD (regardless of cancer diagnosis) were more likely to be men, whereas older adults (age ≥75 years) were more likely to have combined ASCVD and cancer diagnoses. Among the elderly adults with cancer, the most
Any financial toxicity: any difficulty paying medical bills ± unable to pay bills at all ± high financial distress ± cost-related medication non-adherence ± food insecurity ± delayed/foregone care due to cost. The p value for linear trends was <0.001 for all financial toxicity prevalence measures when comparing disease groups. Data in this figure represents weighted prevalence (bars) with 95% confidence interval (error bars). ASCVD = atherosclerotic cardiovascular disease; NHIS = National Health Interview Survey.
frequently reported cancers included breast, prostate, and skin (unknown kind). Similar patterns were observed in the population that reported both ASCVD and cancer (Supplemental Table 2).

Prevalence of FT measures by underlying condition among elderly adults are described in Supplemental Figure 1. Overall, the same pattern was observed for all FT measures as seen with non-elderly adults, although at significantly lower proportions. Individuals reporting ASCVD with or without cancer had a higher degree of difficulty paying medical bills, inability to pay at all, high financial distress, cost-related medication nonadherence, food insecurity, and delayed/foregone medical care due to cost (Supplemental Figure 1). After adjusting for established confounders, presence of ASCVD was associated with a significantly higher odds of any difficulty paying medical bills and being unable of paying them at all when compared with those without ASCVD or cancer (Supplemental Table 4).

### Sensitivity Analyses

Given the high prevalence of nonmelanomatous skin cancer, we performed similar analyses excluding this diagnosis. In addition, we also performed analyses including breast, lung, and colorectal cancer only within our cancer group (i.e., no other cancer diagnoses were included), given their high incidence and mortality. Moreover, given concerns of having varying lengths of time and survival for different cancers and individuals, we performed 2 additional analyses: first, a comparison including only those with an active cancer diagnosis diagnosed within the past year were included; and second, a series of stratified analyses by time since cancer diagnosis (≥0 to <5, ≥5 to <15, and ≥15 years). Overall, the patterns for FT measures remained similar in magnitude and direction among both non-elderly and elderly adults when comparing cancer and/or ASCVD (Supplemental Figures 2 to 13).

### Discussion

In a nationally representative study using data from 2013 to 2018, we found that among non-elderly adults, ASCVD was associated with higher
proportions of overall FT than patients with cancer, and patients with both illnesses concurrently had the worst outcomes across different measures of FT. These results were observed among elderly adults as well, although at significantly lower proportions. These findings demonstrate the severity of FT in patients with ASCVD when compared with cancer, the latter being one of the most researched causes of FT in the current published medical literature (3, 4, 7).

Our findings extend the prior published literature in several ways. First, to our knowledge, this is the first study directly analyzing FT in patients with cancer versus patients with ASCVD. Prior studies have suggested that the effect of ASCVD on FT is likely equivalent to or greater than that of cancer, but this issue had not been definitively investigated (34, 35). In a previous paper, Narang et al. (34) detailed the differences in Medicare beneficiaries with cancer (compared with those without cancer, and sub-stratified by other comorbidities), their out-of-pocket (OOP) expenditures, and financial burden. They showed that individuals with heart disease and/or stroke had higher median OOP expenditures ($2,371 vs. $2,120; p < 0.05) and financial burden (7.0% vs. 5.7%; p < 0.05) when compared with those with cancer in the overall study population. Our results not only confirm that individuals with a diagnosis of cancer have higher odds of all measures of FT than those without cancer nor ASCVD, but also highlight the burden that ASCVD represents in the overall adult population. Second, our study highlights the degree to which patients with these diseases experience financial health-related consequences. Furthermore, we also broaden the scope of the FT phenomenon across all adults, non-elderly and elderly. Our main study population was non-elderly adults, given that these concerns happen approximately in one-third of patients with FT-related issues would like to discuss this problem with their health care providers; however, reports indicate that discussions addressing these concerns happen approximately in one-third of encounters (39) and are often not addressed at all (40-42). There are tools available for clinicians to address this problem. One such validated tool to engage with patients and test for FT is the COMprehensive Score for financial Toxicity (COST), a patient-reported outcome measure to gauge FT in patients.
Financial Toxicity Among ASCVD/Cancer

with cancer, which has been validated in the United States and abroad (43–45). However, to our knowledge, there are currently no tools for clinicians to measure FT among patients with ASCVD. Given the promise shown by COST, future work should develop and validate tools similar to COST for ASCVD patients. Such assessments leveraged proactively (e.g., during annual check-ups) combined with patient education on the costs involved in treatment of chronic cardiovascular conditions may persuade patients to adopt healthier lifestyles that effectively avoid potential FT. For this reason, the American Heart Association and the American College of Cardiology will likely incorporate value and cost in their next guidelines (46). However, as a strong research field in medications, devices, and innovation, cardiology clinicians are lagging behind in terms of FT in an era where treatment permits longer survival for their patients. This is paramount due to patients with cancer and/or ASCVD living longer lives through better and earlier care—which in parallel increases the potential for FT. Even with an aging population, which by definition has higher risk for both diseases and access to universal health coverage, Medicare patients appear to have lower FT, but are still not exempt from it (34,47); this population would ultimately have to deal with problems of a different nature altogether, like caregiver distress and end-of-life care and costs. We hope that by describing the extent of FT in patients with ASCVD, cancer, or both, clinicians will not only be able to provide better care, but will also be able to develop support structures and interventions for the patients experiencing these diseases and FT (48).

**STUDY LIMITATIONS.** First, our study population—those with ASCVD and/or cancer—was based on self-report. Although self-reported conditions can be potentially inaccurate, our estimates agree with those from previous published data using NHIS (12,49,50), and are in line with those reported by national associations, like the American Heart Association and the Centers for Disease Control and Prevention (51,52). Second, we evaluate a limited number of features of FT from health care. Other aspects of financial ill-effects of treatments may not be captured. However, our focus was on domains that have been validated and widely used in prior studies and have shown to correlate well with objective measures of financial burden from OOP costs for medical expenditures (53). Third, questions relating to financial hardship used in NHIS assessed not only whether an individual but also whether anyone in the household had financial hardship, and precludes assessment of the proportion of medical bills directly related to ASCVD and/or cancer and their contribution to financial hardship itself. Khera et al. (13) recently detailed that health care spending on family members with ASCVD represented a mean of 70% of the overall family OOP health spending, with the respective proportion being slightly higher for low-income families. Fourth, it was not possible to differentiate the proportion of financial hardship caused by a specific catastrophic event from the effect of chronic bills. A recent survey suggested that over 60% of individuals with financial hardship from medical bills reported it being tied to a catastrophic medical expense, whereas 1 reports bills for treatment of chronic conditions that have built up over time (54). Fifth, it is difficult to establish causality due to the cross-sectional nature of this study. It is possible that there is a bidirectional relationship between FT and some of its perceived effects on ASCVD and/or cancer. For example, it has been described that food insecurity is often more prevalent in the low-income population (55–57), hinting toward an income-based problem rather than a purely health-related financial consequence. Although it is plausible that causality may be bidirectional (i.e., food insecurity could lead to inadequate financial coping behaviors, or financial hardship could lead to food insecurity) (57), others have argued that health behaviors could potentially be affected by food insecurity (58). Sixth, no adjustments for possible type 1 errors for multiple comparisons were used, so these results should be interpreted with caution. Finally, there is a possibility that the strategies to mitigate FT in cancer have started yielding positive results, and these are reflected in our analyses.

**CONCLUSIONS**

Patients with ASCVD report greater difficulty paying bills and experience high financial distress from medical costs, cost-related medication non-adherence, and food insecurity, and they forego/delay care due to cost at a proportion exceeding those with the population with cancer. It is critical that interventions to mitigate treatment-related costs that have been implemented among cancer patients are evaluated for patients with ASCVD. Finally, we hope
that the findings documented here would serve as the basis for future prospective patient-centered inquiries to investigate patients’ perceptions of FT to inform well-accepted and sustainable interventions.

**FUNDING SUPPORT AND AUTHOR DISCLOSURES**

Dr. Virani has received grant funding from the Department of Veterans Affairs, World Heart Federation and the Jooma and Tahir Family; has received an honorarium from the American College of Cardiology (Associate Editor for Innovations, acc.org); and is the member of a steering committee for the Patient and Provider Assessment of Lipid Management (PALM) registry at the Duke Clinical Research Institute (no financial remuneration). Dr. Krumholz has received research agreements from Medtronic and Johnson & Johnson (Janssen), through Yale, to develop methods of clinical trial data sharing; has received a grant from Medtronic and the Food and Drug Administration, through Yale, to develop methods for postmarket surveillance of medical devices and work under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures that are publicly reported; is chair of a cardiac scientific advisory board for United Health; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science and the Physician Advisory Board for Aetna; and is the founder of Hugo, a personal health information platform. Dr. Nasir is on the advisory board of Amgen, Novartis, Medicine Company; and his research is partly supported by the Jerold B. Katz Academy of Translational Research. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**REFERENCES**

1. Lentz R, Benson AB 3rd, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol 2019;120:85–92.

2. Financial toxicity (financial distress) and cancer treatment (PDQ®)-patient version. Available at: https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-pdq. Accessed February 21, 2019.

3. Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient 2017;10:295–309.

4. Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 2017;109:djw205.

5. Yabroff KR, Dowling EC, Guy GP Jr., et al. Financial hardship associated with cancer in the united states: findings from a population-based sample of adult cancer survivors. J Clin Oncol 2016;34:259–67.

6. Nathan PC, Henderson TO, Kirkhoff AC, Park ER, Yabroff KR. Financial hardship and the economic effect of childhood cancer survivorship. J Clin Oncol 2018;Jco2017764431.

7. Kircher SM, Yarber J, Rutsohn J, et al. Piloting a financial counseling intervention for patients with cancer receiving chemotherapy. J Oncol Pract 2019;15:e202–10.

8. Zafar SY, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB. How should we intervene on the financial toxicity of cancer care? one shot, four perspectives. Am Soc Clin Oncol Educ Book 2017; 37:35–9.

9. Yabroff KR, Gansler T, Wender RC, Cullen KJ, Johnson & Johnson (Janssen), through Yale, to develop methods of clinical trial data sharing; has received a grant from Medtronic and the Food and Drug Administration, through Yale, to develop methods for postmarket surveillance of medical devices and work under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures that are publicly reported; is chair of a cardiac scientific advisory board for United Health; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science and the Physician Advisory Board for Aetna; and is the founder of Hugo, a personal health information platform. Dr. Nasir is on the advisory board of Amgen, Novartis, Medicine Company; and his research is partly supported by the Jerold B. Katz Academy of Translational Research. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**PERSPECTIVES**

COMPETENCY IN MEDICAL KNOWLEDGE: Patients with ASCVD reported higher financial toxicity, irrespective of cancer status (i.e., in those with or without cancer). This association remained significant after adjustment for potential confounders and across age stratification and subanalyses by specific cancer groupings. Patients with both ASCVD and cancer had the highest prevalence of financial toxicity.

TRANSLATIONAL OUTLOOK: Future studies should focus on what the determinants for financial toxicity are in each disease group, and to develop strategies to mitigate these to alleviate health-related economic hardship for patients and care providers.

**ADDRESS FOR CORRESPONDENCE:** Dr. Khurram Nasir, Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart and Vascular Center, Center for Outcomes Research, Houston Methodist, 6550 Fannin Street, Suite 1801, Houston, Texas 77030, USA. E-mail: knasir@houstonmethodist.org, Twitter: @valeromd, @Foud-Chouairi, @rohan_khera, @gowthyharsha, @anshulsaxena, @haiderwarraiach, @virani_md, @nihardesai927, @ProfSasangohar, @hmkyale, @khurramni.
Financial Toxicity Among ASCVD/Cancer

246 Valero-Elizondo et al.

JACC: CARDIOONCOLOGY, VOL. 3, NO. 2, 2021
JUNE 2021:236-46

...care behavior: a 2-year panel study. Health Educ Behav 2018;45:616-24.
18. Dhalliwal KK, King-Shier K, Manns BJ, Hemmelgarn BR, Stone JA, Campbell DJ. Exploring the impact of financial barriers on secondary prevention of heart disease. BMC Cardiovasc Disord 2017;17:61.
19. Ford ES. Food security and cardiovascular disease risk among adults in the United States: findings from the National Health and Nutrition Examination Survey, 2003-2008. Prev Chronic Dis 2013;10:E202.
20. CDC National Center for Health Statistics. Leading causes of death in the United States. Available at: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Accessed February 5, 2021.
21. CDC National Center for Health Statistics. About NHIS. Available at: https://www.cdc.gov/nchs/nhis/about_nhis.htm. Accessed July 13, 2018.
22. Human Subject Regulations Decision Charts: 2018 Requirements. Available at: https://www.hhs.gov/ohrp/regulations-and-policy/decision-charts-2018/index.html. Accessed February 5, 2021.
23. Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 2013;119:3710-7.
24. Rabin DL, Heisler M. Social determinants of health, cost-related nonadherence, and cost-saving strategies in 1,755 outpatient clinic visits. Med Decis Making 2016;36:900-8.
25. Politz K, Cox C. Medical debt among people with health insurance. Kaiser Family Foundation, 2014. Available at: https://www.kff.org/private-insurance/report/medicaledebt-among-people-with-healthinsurance/; Accessed August 15, 2018.
26. Patel MR, Piette JD, Resnicow K, Kovalski-Dobson T, Heisler M. Social determinants of health, cost-related nonadherence, and cost-reducing behaviors among adults with diabetes: findings from the National Health Interview Survey. Med Care 2016;54:796-803.
27. Bickel G, Nord M, Price C, Hamilton W, Cook J. NHIS Data, Questionnaires and Related Documents. About NHIS. Available at: https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm. Accessed July 13, 2018.
28. Seligman HK, Laraia BA, Kushel MB. Food insecurity is associated with chronic disease among low-income NHANES participants. J Nutr 2010;140:304-10.
29. Choi S. Experiencing unmet medical needs or delayed care because of cost: foreign-born adults in the U.S. by region of birth. Int J Health Serv 2016;46:693-711.
30. Joosten MN, Paj JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA 2012;308:1660-7.
31. Valero-Elizondo J, Salami JA, Ogumoroti O, et al. Favorable cardiovascular risk profile is associated with lower healthcare costs and resource utilization the 2012 Medical Expenditure Panel Survey. Circ Cardiovasc Qual Outcomes 2016;9:143-53.
32. Seligman HK, Laraia BA, Kushel MB. Food insecurity is associated with chronic disease among low-income NHANES participants. J Nutr 2010;140:304-10.
33. Choi S. Experiencing unmet medical needs or delayed care because of cost: foreign-born adults in the U.S. by region of birth. Int J Health Serv 2016;46:693-711.
34. Osborn C, Kripalani S, Goggins KM, Wallston KA. Financial strain is associated with medication nonadherence and worse self-rated health among cardiovascular patients. J Health Care Poor Underserved 2012;28:499-513.
35. Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 2018;6:166.
36. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 2013;18:381-90.
37. Shankaran V, Ramsey S. Addressing the financial burden of cancer treatment: from copay to can’t pay. JAMA Oncol 2015;1:273-4.
38. Hunter WG, Zhang CZ, Hesson A, et al. What strategies do physicians and patients discuss to reduce out-of-pocket costs? Analysis of cost-saving strategies in 1,755 outpatient clinic visits. Med Decis Making 2016;36:900-10.
39. Meissenberg BR, Varner A, Ellis E, et al. Patient attitudes regarding the cost of illness in cancer care. Oncologist 2015;20:1199-204.
40. Meeker CR, Geynisman DM, Egleston BL, et al. Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer. J Oncol Pract 2016;12:e755-64.
41. Meeker CR, Geynisman DM, Egleston BL, et al. Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer. J Oncol Pract 2016;12:e755-64.
42. Meeker CR, Geynisman DM, Egleston BL, et al. Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer. J Oncol Pract 2016;12:e755-64.
43. de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the Comprehensive Score for financial Toxicity (COST). Cancer 2017;123:476-84.
44. Honda K, Gywali B, Ardo M, et al. Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer. J Glob Oncol 2019;5:1-8.
45. Ripamonti C, Chiesi F, Di Pede P, et al. The validation of the Italian version of the Comprehensive Score for financial Toxicity (COST). Supportive Care Cancer 2020;28:4475-87.
46. Hlatky MA. Considering cost-effectiveness in cardiology clinical guidelines: progress and prospects. Value Health 2016;19:516-9.
47. Davis K, Stremikis K, Doty MM, Zeeza MA. Medicare beneficiaries less likely to experience cost- and access-related problems than adults with private coverage. Health Aff (Millwood) 2012;31:1866-75.